Tenax Therapeutics (TENX) EBT (2010 - 2026)

Tenax Therapeutics has disclosed EBT across 16 years of filings, most recently posting -$17.8 million for Q2 2026.

• In Q2 2026, EBT fell 64.26% year-over-year to -$17.8 million; the TTM figure through Jun 2026 stood at -$64.8 million (down 106.0% YoY), while the FY2025 annual figure was -$52.6 million, down 198.62% from the prior year.
• EBT came in at -$17.8 million for Q2 2026 at Tenax Therapeutics, down from -$15.7 million in the prior quarter.
• In the past five years, EBT ranged from a high of $2.9 million in Q3 2022 to a low of -$17.8 million in Q2 2026.
• Average EBT over 5 years is -$5.7 million, with a median of -$3.9 million recorded in 2024.
• Year-over-year, EBT surged 104.1% in 2022 and plunged 580.63% in 2023.
• Over 5 years, EBT stood at $2.6 million in 2022, then sank by 580.63% to -$12.3 million in 2023, then surged by 48.96% to -$6.3 million in 2024, then sank by 147.82% to -$15.5 million in 2025, then slipped by 14.63% to -$17.8 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$17.8 million in Q2 2026, -$15.7 million in Q1 2026, and -$15.5 million in Q4 2025.